Case Control Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2022; 14(7): 1281-1294
Published online Jul 15, 2022. doi: 10.4251/wjgo.v14.i7.1281
Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study
Kazuhisa Takeda, Yu Sawada, Yasuhiro Yabushita, Yuki Honma, Takafumi Kumamoto, Jun Watanabe, Ryusei Matsuyama, Chikara Kunisaki, Toshihiro Misumi, Itaru Endo
Kazuhisa Takeda, Yu Sawada, Jun Watanabe, Chikara Kunisaki, Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Yasuhiro Yabushita, Yuki Honma, Takafumi Kumamoto, Ryusei Matsuyama, Itaru Endo, Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Jordan
Toshihiro Misumi, Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan
Author contributions: Takeda K, Sawada Y, Yabushita Y, Honma Y, Kumamoto T and Watanabe J performed the research; Takeda K drafted the manuscript; Kunisaki C, Misumi T and Endo I revised the manuscript critically; all authors read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved for publication by our Institutional Reviewer.
Informed consent statement: The requirement for written informed consent was waived owing to the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Kazuhisa Takeda, PhD, Assistant Professor, Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan.
Received: February 1, 2022
Peer-review started: February 1, 2022
First decision: April 17, 2022
Revised: April 29, 2022
Accepted: June 4, 2022
Article in press: June 4, 2022
Published online: July 15, 2022
Core Tip

Core Tip: Hepatectomy is the mainstay of treatment for patients with colorectal liver metastases (CRLMs). However, there are cases of early recurrence after upfront hepatectomy alone. In selected high-risk patients, neoadjuvant chemotherapy (NAC) may improve long-term survival. Although several studies have identified risk factors for recurrence and prognosis after hepatectomy for CRLMs, they could not show a benefit of NAC for resectable CRLMs. This article demonstrated the effectiveness of NAC for initially resectable CRLMs, based on risk stratification according to prognostic factors.